Diagnos Inc's stock has seen a notable decline this week amidst news of financial adjustments.
This week, Diagnos Inc (ADK.V) experienced a significant drop in its stock price, closing at C$0.23, down 11.54% on the day and 13.21% over the week. The company has been in the news recently due to amendments related to its convertible debentures and a brokered private placement.
Advertisement
Diagnos Inc
ADK.V
ADK.V
Diagnos Inc
WealthAwesomeAdvertisement
Market cap
$45.76M
52W high
$0.42
52W low
$0.18
1W change
+24.19%
Beta
-0.15
Analyst Price Targets
Based on analyst covering ADK
Wall Street analysts forecast ADK stock price to rise 289.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$1.50
+289.6% Upside
Current Price
C$0.39
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ADK's historical volatility
30-Day Vol
87.0%
Annualized
90-Day Vol
69.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.46
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.41 | C$0.30 – C$0.55 |
| 60 trading days | C$0.43 | C$0.28 – C$0.66 |
| 90 trading days | C$0.46 | C$0.27 – C$0.77 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should monitor the developments surrounding Diagnos Inc's financing activities and consider the implications of its recent stock performance and technical indicators.
Diagnos Inc's stock down 11.54% today, with a market cap of C$27.69 million.
The stock has a 52-week trading range of C$0.18 to C$0.42, currently sitting at 19% of its range, indicating potential volatility.
Bull case
Analysts have set an average target price of C$1.50 for Diagnos Inc, which suggests there could be significant upside from its current price. This outlook might attract investors looking for growth opportunities.
Bear case
However, the company has faced a year-to-date decline of 36.11% and has a negative return on equity of -990.3%. These figures raise serious concerns about the company’s financial health.
Recent Price Action
Diagnos Inc's stock has faced substantial volatility this week, closing at C$0.23, marking an 11.54% decline on Friday and a total decrease of 13.21% over the week. This performance follows a month where the stock rose by 15.00%, indicating a sharp reversal in sentiment.
Company News and Catalysts
Advertisement
Recent headlines surrounding Diagnos Inc include an amendment to its unsecured convertible debentures, which extends the maturity date to March 1, 2027, and reduces the conversion price to C$0.32 while maintaining a 10% annual interest rate. Additionally, the company closed a non-brokered private placement, raising C$640,050.95 by issuing 1,828,717 units at C$0.35 per unit. These developments may have contributed to the stock's recent fluctuations.
Technical Picture
From a technical standpoint, Diagnos Inc is currently trading at its 50-day moving average of C$0.23, indicating no immediate change. However, it is significantly below its 200-day moving average of C$0.29, suggesting a bearish trend. The stock's 52-week range of C$0.18 to C$0.42 places it at 19% of its range, highlighting potential volatility. The beta of -0.16 indicates lower volatility compared to the market.
Insider Activity
No recent insider activity has been reported for Diagnos Inc, which may suggest a wait-and-see approach among current stakeholders.
Price Action Summary
As of the last close, Diagnos Inc stock stands at C$0.23, reflecting a notable decline of 11.54% for the day. Investors should remain vigilant as the company navigates its financial adjustments and market conditions.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
